Rchr
J-GLOBAL ID:201701015334641234   Update date: Sep. 01, 2021

KOSUKE HASHIMOTO

ハシモト コウスケ | KOSUKE HASHIMOTO
Affiliation and department:
Research theme for competitive and other funds  (1):
  • 2020 - 2021 免疫チェックポイント阻害薬の適切な投与間隔・期間、有害事象回避のアルゴリズム開発
Papers (14):
  • Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Hiroshi Kagamu. Detection of pseudoprogression with [ 18 F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European journal of nuclear medicine and molecular imaging. 2020. 481. 1268-1270
  • Miura Y, Mouri A, Kaira K, Yamaguchi O, Shiono A, Hashimoto K, Nishihara F, Shinomiya S, Akagami T, Murayama Y, et al. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. Thoracic Cancer. 2020. 11. 5. 1280-1287
  • Yamaguchi O, Kaira K, Kawasaki T, Mouri A, Hashimoto K, Shiono A, Shinomiya S, Miura Y, Nishihara F, Murayama Y, et al. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. Thorac Cancer. 2020. 11. 4. 1045-1051
  • Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, et al. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. Thoracic Cancer. 2020. 11. 1280-1287
  • Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, Kenichi Yoshimura, Katsuhisa Horimoto, Masashi Kitazawa, Kazuhiko Fukui, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, et al. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. cancer immunology resarch. 2020. 8. 3. 334-344
more...
Lectures and oral presentations  (2):
  • Role of FDG uptake as predictivie marker of PD-1 inhibitor in patients with previously non-small cell lung cancer
    (2020)
  • Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer
    (2020)
Education (1):
  • 2015 - 2021 Saitama Medical University
Professional career (1):
  • 医学博士 (埼玉医科大学大学院)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page